AstraZeneca UK Limited
Industry / private company
Location:
London,
United Kingdom (GB)
ISNI: 0000000459294381
ROR: https://ror.org/04r9x1a08
PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy (2019)
Girard N, Mornex F, Christoph DC, Fietkau R, Filippi AR, Field J, Garrido Lopez P, et al.
Conference contribution
The transcription factor c-Myb regulates CD8+T cell stemness and antitumor immunity (2019)
Gautam S, Fioravanti J, Zhu W, Le Gall JB, Brohawn P, Lacey NE, Hu J, et al.
Journal article
Distinct spatio-temporal dynamics of tumor-associated neutrophils in small tumor lesions (2019)
Sody S, Uddin M, Grüneboom A, Goergens A, Giebel B, Gunzer M, Brandau S
Journal article
Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA (2019)
Janssens R, Russo S, van Overbeeke E, Whichello C, Harding S, Kübler J, Juhaeri J, et al.
Journal article
Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT) (2018)
Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, et al.
Journal article
Proteolytic activation of the human epithelial sodium channel by trypsin IV and trypsin I involves distinct cleavage sites (2014)
Härteis S, Krappitz A, Krappitz M, Murphy JE, Bertog M, Krüger B, Nacken R, et al.
Journal article
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients (2014)
Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, et al.
Journal article